Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact email@example.com.
SOURCE DURECT Corporation
CUPERTINO, Calif., June 9, 2014 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that Matt Hogan, Chief Financial Officer, will be presenting at The 25th Annual Wall Street Analyst Forum Institutional Investor Conference on Thursday, June 19 at 10:35 a.m. Eastern Time. The conference is being held at the University Club located at 1 West 55th Street in New York City.
A live audio webcast of the presentation will be available by accessing http://www.visualwebcaster.com/event.asp?id=99581.
A live audio webcast of the presentation will also be available by accessing DURECT's homepage at www.durect.com and clicking "Investor Relations." If you are unable to participate during the live webcast, the call will be archived on DURECT's website under Audio Archive in the "Investor Relations" section.
About DURECT Corporation
DURECT is a specialty pharmaceutical company developing innovative drugs for pain and other chronic diseases, with late-stage development programs including Remoxy®, POSIDUR™, ELADUR®, and TRANSDUR®-Sufentanil. DURECT's proprietary oral, transdermal and injectable depot delivery technologies enable new indications and superior clinical/commercial attributes such as abuse deterrence, improved convenience, compliance, efficacy and safety for small molecule and biologic drugs. For more information, please visit www.durect.com.
NOTE: POSIDUR™, SABER™, ORADUR®, TRANSDUR®, and DURIN® are trademarks of DURECT Corporation. Other referenced trademarks belong to their respective owners. REMOXY, POSIDUR, ELADUR® and TRANSDUR-Sufentanil are drug candidates under development and have not been approved for commercialization by the U.S. Food and Drug Administration or other health authorities.
©2012 PR Newswire. All Rights Reserved.